To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Study Purpose

This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd to that of the marketed product Taclonex® topical suspension of Leo Pharma Inc. in the treatment of scalp psoriasis.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female subjects aged at least 18 years at Visit 1. 2. A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp and clinical signs of psoriasis vulgaris on trunk and/or limbs. 3. A PGA of disease severity of the scalp psoriasis consistent with at least moderate disease severity (Grade ≥ 3). 4. A plaque elevation of at least moderate severity (Grade ≥ 3) at the scalp target lesion site. The most severe scalp lesion at baseline should be identified as the target lesion.

Exclusion Criteria:

1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative, or pustular psoriasis. 2. Other inflammatory skin disease in the scalp that may confound the evaluation of the scalp psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea capitis). 3. Presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in the scalp that could interfere with the rating of efficacy parameters. 4. Presence of viral lesions, fungal, bacterial, or parasitic infections and/or atrophic (thinning) skin on the scalp. 5. History of psoriasis unresponsive to topical treatments. 6. Subjects with planned phototherapy and/or exposure to ultraviolet A (UVA) and/or UVB during the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03331523
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Glenmark Pharmaceuticals Ltd. India
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

William Todd Kays
Principal Investigator Affiliation Glenmark Pharmaceuticals Inc., USA
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Scalp Psoriasis

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Investigational Site 24, Encinitas, California

Status

Recruiting

Address

Investigational Site 24

Encinitas, California, 92024

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 3, Fremont, California

Status

Recruiting

Address

Investigational Site 3

Fremont, California, 94538

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 13, San Diego, California

Status

Recruiting

Address

Investigational Site 13

San Diego, California, 92108

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 20, San Diego, California

Status

Recruiting

Address

Investigational Site 20

San Diego, California, 92123

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 32, Santa Monica, California

Status

Recruiting

Address

Investigational Site 32

Santa Monica, California, 90404

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 14, Denver, Colorado

Status

Recruiting

Address

Investigational Site 14

Denver, Colorado, 80220

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 1, Miami, Florida

Status

Recruiting

Address

Investigational Site 1

Miami, Florida, 33144

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 30, Miami, Florida

Status

Recruiting

Address

Investigational Site 30

Miami, Florida, 33175

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 7, Miramar, Florida

Status

Recruiting

Address

Investigational Site 7

Miramar, Florida, 33027

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 22, Tampa, Florida

Status

Recruiting

Address

Investigational Site 22

Tampa, Florida, 33609

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 15, New Albany, Indiana

Status

Recruiting

Address

Investigational Site 15

New Albany, Indiana, 47150

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 10, South Bend, Indiana

Status

Recruiting

Address

Investigational Site 10

South Bend, Indiana, 46617

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 21, Louisville, Kentucky

Status

Recruiting

Address

Investigational Site 21

Louisville, Kentucky, 40241

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 6, Ann Arbor, Michigan

Status

Recruiting

Address

Investigational Site 6

Ann Arbor, Michigan, 48103

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 12, Fridley, Minnesota

Status

Recruiting

Address

Investigational Site 12

Fridley, Minnesota, 55432

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 26, Saint Joseph, Missouri

Status

Recruiting

Address

Investigational Site 26

Saint Joseph, Missouri, 64506

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 17, Henderson, Nevada

Status

Recruiting

Address

Investigational Site 17

Henderson, Nevada, 89052

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 25, Las Vegas, Nevada

Status

Recruiting

Address

Investigational Site 25

Las Vegas, Nevada, 89128

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 29, Forest Hills, New York

Status

Recruiting

Address

Investigational Site 29

Forest Hills, New York, 11375

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 28, Rochester, New York

Status

Recruiting

Address

Investigational Site 28

Rochester, New York, 14623

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 4, High Point, North Carolina

Status

Recruiting

Address

Investigational Site 4

High Point, North Carolina, 27262

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 18, Fountain Inn, South Carolina

Status

Recruiting

Address

Investigational Site 18

Fountain Inn, South Carolina, 29644

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 27, Mount Pleasant, South Carolina

Status

Recruiting

Address

Investigational Site 27

Mount Pleasant, South Carolina, 29464

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 9, Knoxville, Tennessee

Status

Recruiting

Address

Investigational Site 9

Knoxville, Tennessee, 37922

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 8, Nashville, Tennessee

Status

Recruiting

Address

Investigational Site 8

Nashville, Tennessee, 37215

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 5, Austin, Texas

Status

Recruiting

Address

Investigational Site 5

Austin, Texas, 78759

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 11, College Station, Texas

Status

Recruiting

Address

Investigational Site 11

College Station, Texas, 77845

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 16, San Antonio, Texas

Status

Recruiting

Address

Investigational Site 16

San Antonio, Texas, 78213

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 19, San Antonio, Texas

Status

Recruiting

Address

Investigational Site 19

San Antonio, Texas, 78249

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 31, Norfolk, Virginia

Status

Recruiting

Address

Investigational Site 31

Norfolk, Virginia, 23507

Site Contact

Central Contact

91 22 6138 3131

Investigational Site 23, Richmond, Virginia

Status

Recruiting

Address

Investigational Site 23

Richmond, Virginia, 23294

Site Contact

Central Contact

91 22 6138 3131

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.